Award? goes to biochemists Virginijus Siksnys, whose lab independently developed the gene-editing tool, Emmanuelle Charpentier and Jennifer Doudna.

For more information, you can visit the festival?s website at: stemcellfestival.com

In research published today in the journal Cell Stem Cell, scientists at Columbia University Vagelos College of Physicians and Surgeons present the most definitive evidence to date that the human brain makes new neurons throughout life.

A new Japanese joint venture company called MAGiQ Therapeutics ? the result of a collaboration between Q Therapeutics and Reprocell ? aims to develop cell and gene therapies for demyelinating and degenerative diseases of the central nervous system.

The Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel) ? a CAR-T cell therapy ? for the treatment of adult patients who have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have relapsed or are ineligible for an autologous stem cell transplant (ASCT).

. By using this method, scientists from the German Primate Center (DPZ) __ Leibniz Institute for Primate Research have discovered a quicker and more efficient treatment for the cells.

The incidence of heart disease is on the rise, and new therapeutic strategies are needed. Approaches based on stem cells, which can potentially preserve or even regenerate heart muscle cells damaged by ischemia ? a hallmark of heart disease ? are especially promising. Now, thanks to an $11.6-Million Program Project Grant (PPG) from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) under award number P01HL134608, scientists at the Lewis Katz School of Medicine at Temple University (LKSOM) are poised to explore new possibilities in stem cell-based treatments for heart repair and regeneration.

Injecting minute amounts of two immune-stimulating agents directly into solid tumors in mice can eliminate all traces of cancer in the animals, including distant, untreated metastases, according to a study by researchers at the Stanford University School of Medicine.

The first company-sponsored clinical trials of the gene editing system will treat genetic blood diseases

A modified version of iPS methodology, called interrupted reprogramming, allows for a highly controlled, potentially safer, and more cost-effective strategy for generating progenitor-like cells from adult cells.